Investor Perspectives Panel Discussion: What Drives Philanthropic & Venture Investment in the Challenging Glioblastoma Landscape?

• Discussing key milestones, translatable models and biomarkers that are prioritized by investors to mitigate the high-risk nature of GBM drug development
• Exploring how philanthropic funds can de-risk early-stage assets for later VC investment, highlighting overlapping interests and divergencies and how to create a compelling value-proposition for both
• Managing venture philanthropy co-investments, public-private partnerships, and strategic alliances, that are essential for accelerating the development of transformative therapies in this challenging field

Speakers:

Sam Blackman

EIR

Google Ventures

Jonathan Pritz

Investment Director

RA Capital Management

Yash Thukral

Executive Director

White Lion Capital LLC

John Higgins

Managing Director

Brain Tumor Investment Fund